Clinical treatment effect was demonstratedby significantly decreased AD severity scores at the end of treatment.At v10 versus v2, the percentages of CD4+ interleukin-producing cellsshowed a decreasing trend in ISF L and NL, unbound IL-4 levels inplasma were increased, IL-5 levels in ISF L reduced, and levels offactors involved in anti-inflammatory pathways and re-epithelizationincreased. Here, IL4 is linked to Alzheimer disease.